CRCM  Vol.4 No.10 , October 2015
Safety and Efficacy of PTCTS Cosmetic Gel: Study on Human Radiodermatitis Lesions
Radiodermatitis is a constant complication after radiotherapy with no efficient drug for prevention and treatment. Its physiopathology is complex, possibly related to injury of epidermis and endothelial cells from the basal layer by radiolysis, overproduction of free radicals, pro-inflammatory cytokines, and inflammation. PTCTS gel is an after sun cosmetic gel composed by anti-oxidative plant extract rich in natural nanoparticles and thermal water (Complex A) and recombinant protein of Trypanosoma cruzi transialidase (Complex B), with high anti-oxidative and anti-apoptotic effects, presenting anti-aging and healing cutaneous properties. Objective: To study the safety and efficacy of PTCTS gel for topic use in volunteer subjects with healthy skin, and in patients with radiodermatitis, in different concentrations of Complexes A and B. Material and Methods: The project was approved by the Ethical Committee of Arnaldo Vieira de Carvalho Institute, Sao Paulo, Brazil. The individuals were submitted to laboratorial toxicity study through tests for liver and kidney function, levels of blood glucose and blood count before and after 7 days of PTCTS application. We studied two groups: GI-22 volunteers with healthy skin, presenting articular or skeletal muscle pain and GII-38 patients in radiotherapy for breast or head and neck cancer, with radiodermatitis grade 2 or 3. The patients were evaluated before and after 1.0 ml/cm2 PTCTS gel application, twice a day. We tested Complex B in four different concentrations, and Complex A concentrations varied inversely. Results: No irritation signs were observed in GI nor GII group, 64% of GI had important decrease in the intensity of the muscular or articular pain, and 99% of GII showed regression of radiodermatitis, all exhibiting relief of pain. No patient presented hematologic, renal or hepatic toxicity. Conclusion: PTCTS cosmetic gel is a safe option for radiodermatitis treatment, with no side effects or laboratorial toxicity in different concentrations. This product presented excellent clinical results even if used diluted 4 times more than the original product and may be a good option for treatment of radiodermatitis. Further studies may show if it is also indicated in the prevention of the lesion, and if it is better than products containing corticoids.

Cite this paper
Graziani, S. , Van Eyll, B. , Fristachi, C. , Lourdes Higuchi, M. , Ikegami, R. and Ramires, J. (2015) Safety and Efficacy of PTCTS Cosmetic Gel: Study on Human Radiodermatitis Lesions. Case Reports in Clinical Medicine, 4, 327-333. doi: 10.4236/crcm.2015.410065.
[1]   Gosselin, T.K., Schneider, S.M., Plambeck, M.A. and Rowe, K. (2010) A Prospective Randomized, Placebo-Controlled Skin Care Study in Women Diagnosed with Breast Cancer Undergoing Radiation Therapy. Oncology Nursing Forum, 37, 619-626.

[2]   Maddocks-Jennings, W., Wilkinson, J.M. and Shillington, D. (2005) Novel Approaches to Radiotherapy-Induced Skin Reactions: A Literature Review. Complementary Therapies in Clinical Practice, 11, 224-231.

[3]   McQuestion, M. (2011) Evidence-Based Skin Care Management in Radiation Therapy: Clinical Update. Seminars in Oncology Nursing, 27, e1-e17.

[4]   Guo, H., Callaway, J.B. and Ting, J.P. (2015) Inflammasomes: Mechanism of Action, Role in Disease, and Therapeutics. Nature Medicine, 21, 677-687.

[5]   Franchi, L., Eigenbrod, T., Munoz-Planillo, R. and Nunez, G. (2009) The Inflammasome: A Caspase-1-Activation Platform That Regulates Immune Responses and Disease Pathogenesis. Nature Immunology, 10, 241-247.

[6]   Stoecklein, V.M., Osuka, A., Ishikawa, S., Lederer, M.R., Wanke-Jellinek, L. and Lederer, J.A. (2015) Radiation Exposure Induces Inflammasome Pathway Activation in Immune Cells. Immunology, 194, 1178-1189.

[7]   Crocker, P.R. and Redelinghuys, P. (2008) Siglecs as Positive and Negative Regulators of the Immune System. Biochemical Society Transactions, 36, 1467-1471.

[8]   McCormack, H.M., Horne, D.J. and Sheather, S. (1988) Clinical Applications of Visual Analogue Scales: A Critical Review. Psychological Medicine, 18, 1007-1019.

[9]   Sitton, E. (1992) Early and Late Radiation-Induced Skin Alterations. Part 1: Mechanisms of Skin Changes. Oncology Nursing Forum, 19, 801-807.

[10]   Glean, E., Edwards, S., Faithfull, S., Meredith, C., Richards, C., Smith, M. and Colyer, H. (2001) Intervention for Acute Radiotherapy Induced Skin Reactions in Cancer Patients: The Development of a Clinical Guideline Recommended for Use by the College of Radiographers. Journal of Radiotherapy in Practice, 2, 75-84.

[11]   Hopewell, J.W. (1990) The Skin: Its Structure and Response to Ionizing Radiation. International Journal of Radiation Biology, 57, 751-773.

[12]   Cox, J.D., Byhardt, R.W., Wilson, F., Haas, J.S., Komaki, R. and Olson, L.E. (1986) Complications of Radiation Therapy and Factors in Their Prevention. World Journal of Surgery, 10, 171-188.

[13]   Meghrajani, C.F., Co, H.C., Ang-Tiu, C.M. and Roa, F.C. (2013) Topical Corticosteroid Therapy for the Prevention of Acute Radiation Dermatitis: A Systematic Review of Randomized Controlled Trials. Expert Review of Clinical Pharmacology, 6, 641-649.

[14]   Bolderston, A., Lloyd, N.S., Wong, R.K., Holden, L. and Robb-Blenderman, L., the Supportive Care Guidelines Group of Cancer Care Ontario Program in Evidence-Based Care (2006) The Prevention and Management of Acute Skin Reactions Related to Radiation Therapy: A Systematic Review and Practice Guideline. Supportive Care in Cancer, 14, 802-817.

[15]   Nystedt, K. (2007) In Response to the Article “The Prevention and Management of Acute Skin Reactions Related to Radiation Therapy: A Systematic Review and Practice Guideline” (Bolderston et al. 2006). Supportive Care in Cancer, 15, 1219.

[16]   Herst, P.M., Bennett, N.C., Sutherland, A.E., Peszynski, R.I., Paterson, D.B. and Jasperse, M.L. (2014) Prophylactic use of Mepitel Film Prevents Radiation-Induced Moist Desquamation in an Intra-Patient Randomised Controlled Clinical Trial of 78 Breast Cancer Patients. Radiotherapy and Oncology, 110, 137-143.

[17]   Hawker, G.A., Mian, S., Kendzerska, T. and French, M. (2011) Measures of Adult Pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care & Research, 63, S240-S252.

[18]   Higuchi, M.L., Santos, M.H.H., Fagundes, R.Q., Palomino, S.A.P. and Reis, M.M. (2011) Trans-Sialidase from Trypanosoma cruzi: An Anti-Atherosclerotic Drug. Keystone Symposia on Molecular and Cellular Biology, Snowbird, 3-7 April 2011, 66.

[19]   Greenberg, S. and Grinstein, S. (2002) Phagocytosis and Innate Immunity. Current Opinion in Immunology, 14, 136-145.

[20]   Hansson, G.K., Libby, P., Schonbeck, U. and Yan, Z.Q. (2002) Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis. Circulation Research, 91, 281-291.